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Cell adhesion molecules play a signiﬁcant role in cancer progression and metastasis. Cell-cell interactions of cancer cells with
endothelium determine the metastatic spread. In addition, direct tumor cell interactions with platelets, leukocytes, and soluble
components signiﬁcantly contribute to cancer cell adhesion, extravasation, and the establishment of metastatic lesions. Clinical
evidence indicates that heparin, commonly used for treatment of thromboembolic events in cancer patients, is beneﬁcial for their
survival. Preclinical studies conﬁrm that heparin possesses antimetastatic activities that lead to attenuation of metastasis in various
animal models. Heparin contains several biological activities that may aﬀect several steps in metastatic cascade. Here we focus on
the role of cellular adhesion receptors in the metastatic cascade and discuss evidence for heparin as an inhibitor of cell adhesion.
While P- and L-selectin facilitation of cellular contacts during hematogenous metastasis is being accepted as a potential target of
heparin, here we propose that heparin may also interfere with integrin activity and thereby aﬀect cancer progression. This review
summarizes recent ﬁndings about potential mechanisms of tumor cell interactions in the vasculature and antimetastatic activities
of heparin.
1.Introduction
Metastasis is facilitated by cell-cell interactions between
tumor cells and the endothelium in distant tissues. Tumor
cells in circulation interact also with platelets and leukocytes
thatfurthercontributetotumorcelladhesion,extravasation,
and the establishment of metastatic lesions. Hematogenous
cancer metastasis is a multistep cascade encompassing pro-
cess, starting with local invasion of tumor cells at primary
tumors, survival in systemic circulation, extravasation in
secondary sites, and ending with establishment of growing
metastatic lesions. The metastatic capacity of tumor cells
correlateswiththeirabilitytoexitfromthebloodcirculation,
to colonize distant organs, and to grow in distant organs [1].
The organ-speciﬁc character of metastasis has been already
observed by S. Paget more than a century ago, and the “seed
and soil” hypothesis postulates speciﬁc interactions of tumor
cells with the “friendly” environment of distant organs
that enables the establishment of metastasis and subsequent
growth [2]. While cell-cell interactions facilitating tumor cell
adhesion in the vasculature of speciﬁc organs are essential
steps in the metastatic cascade, inhibition of these interac-
tions represent a therapeutically useful target for attenuation
of metastasis (Figure 1). Two major cell adhesion molecule
families, selectins and integrins, have been identiﬁed to
participateinmetastasis[3–6].Inadditiontodirecttargeting
of selectin and integrins, recent evidence suggests that
heparin possesses selectin (P- and L-selectin) and also inte-
grin inhibitory activity [7–9]. Heparin and low-molecular-
weight (LMW) heparin are commonly used anticoagulants
for treatment of cancer-associated thromboembolism in
cancer patients [10, 11]. The exact mechanism of cell-
cell interactions involved in cancer progression remains to
be fully elucidated; however, the potential of heparins to
interfere with this process warrants further investigations.2 International Journal of Cell Biology
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Figure 1: Selectins and integrins contribute to metastatic spread. (a) Schematic presentation of selectin- and integrin-mediated cancer
cell interactions with several blood constituents (e.g., platelets, leukocytes, and endothelial cells) during hematogenous metastasis. (b)
Heparin application in mouse models blocks both P- and L-selectin-mediated; and VLA4-mediated interactions of cancer cells within blood
circulation thereby aﬀecting metastasis.
2. CellAdhesion asa Determinantof Metastasis
Withinbloodvessels,circulatingtumorcellsultimatelyinter-
act with the endothelium that might lead to tumor cell ar-
rest and extravasation (Figure 1). Studies of tumor cell-
endothelial contact formations have been based on parallels
to the leukocyte-endothelial cell interactions during inﬂam-
mation. Although the mechanism of tumor cell adhesion
certainly diﬀers from leukocyte recruitment to inﬂammatory
sites, the cell adhesion molecules involved in the contact
formation with endothelium are potentially the same [3,
5, 6]. Indeed, there is accumulating evidence for the role
of selectins and integrins in cancer progression of various
cancer types, including colon and lung carcinomas and
melanomas[5,6].Whileselectin-mediatedtumorcellsarrest
and adhesion contribute to metastasis, integrin-mediated
interaction from both tumor cells and the surrounding envi-
ronment further contribute to cancer progression.
3.Selectins
Selectins are vascular cell adhesion molecules involved in
adhesive interactions of leukocytes and platelets and en-
dothelium within the blood circulation. There are three
members of the selectin family: P-, E-, and L-selectin.
P-selectin is present in the storage granules of platelets
(α-granules) and endothelial cells (Weibel-Palade bodies),
thus enabling rapid translocation on cell surfaces upon
activation [12]. On the contrary, endothelial expression of E-
selectin requires de novo transcription, leading to expression
on activated endothelial cell surfaces several hours after
stimulation [12]. L-selectin is constitutively expressed on cell
surfaces of almost all leukocyte subpopulations. The physio-
logical functions of selectins are well described in processes
of inﬂammation, immune response, wound repair, and
hemostasis [13]. The role of selectins in these processes has
been elucidated in mouse deﬁcient in individual selectins.International Journal of Cell Biology 3
Whereas L-selectin mediates fast rolling of leukocytes on
endothelium, P- and E-selectins support rolling at lower
velocities [13]. The initial steps in leukocyte tethering and
rollingonendotheliumaresupportedbyrapidandreversible
interactions of selectins with their carbohydrate ligands.
The majority of selectin ligands consist of distinct glycan
structures carrying the terminal core tetrasaccharide struc-
ture sialyl Lewisx/a (sLex/sLea)o nap r o t e i nb a c k b o n e[ 14,
15]. Selectins binds to various classes of molecules (mucins,
sulfated glycolipids, glycosaminoglycans), and most of these
molecules were shown to be functional selectin ligands in
vivo [12]. Eﬃcient selectin binding to carbohydrates usually
requires a proper glycoprotein scaﬀold that presents several
selectin ligands in clusters, thereby increasing the avidity of
the interaction.
3.1.SelectinsasFacilitatorsofMetastasis. Hematogenousme-
tastasis is the common route for cancer spread of epithelial
cancers—carcinomas. In the normal physiological state,
epithelial cells line the lumen of hollow organs and are
covered by mucins that are either cell surface attached or
building soluble layers covering the epithelium. Mucins are
high-molecular-weight molecules with a large proportion
of O-linked glycans attached to a protein backbone. Dur-
ing malignant transformation cell surface glycans undergo
dramatic changes [16]. The major alterations of glycans
on tumor cells are associated with enhanced expression of
sLex or its isomer sLea, Tn and sialyl-Tn antigen structures
[16, 17]. Enhanced expression of sLex and sLea structures is
frequently associated with progression and poor prognosis
in various cancers including colon, gastric, lung, renal, and
breast cancers, melanomas, and others (reviewed in [18]).
Several laboratories have shown that at least one selectin (P-,
L-, or E-) is capable to bind to any human carcinoma tested
(e.g., [19, 20]), which emphasize the potential of selectins
to mediate contacts with tumor cells within vasculature.
The fact that, during the hematogenous phase of metastasis,
selectin ligand-carrying tumor cells may encounter selectins,
present on blood constituents (leukocytes, platelet, and
endothelium) in the circulation, supported the notion of
selectin involvement in metastatic progression [3, 5]. This
hypothesis has been evaluated by several laboratories, and
recent ﬁndings using mouse models deﬁcient in one or more
selectins conﬁrmed the involvement of P-, L-, and also E-
selectin in metastasis [7, 21–24].
3.2. P-Selectin and Metastasis. The rapid expression of P-
selectinoncellsurfacesofendothelialcellsandplateletsupon
activation makes P-selectin a likely candidate involved in
the metastatic process. There is accumulating evidence that
formation of platelet-tumor cell thrombi helps evading host
responses, thereby contributing to metastasis [7, 25–27]. In
the absence of platelet-tumor cell interactions, tumor cells
are cleared by NK cells [26, 28]. Minimal platelet-tumor cell
microthrombi has been detected in the absence of P-selectin,
leading to reduced tumor cell adhesion in the lungs of
mice and subsequently attenuation of metastasis [7, 22, 29].
Furthermore, removal of cell surface mucins from tumor
cells prior to intravenous injection resulted in reduction of
metastasis [7]. Bone marrow reconstitution experiments in
P-selectin-deﬁcient mice have shown that endothelial P-
selectin, in addition to platelet P-selectin, contributes to
metastasis [29].
Patientswithmetastaticcarcinomacancerareathighrisk
for thromboembolic events, a ﬁnding initially described by
Trousseau [30]. The association between mucinous car-
cinoma and Trousseau’s syndrome led to the hypothesis
that mucin might directly induce thrombi formation [31].
Intravenous injection of puriﬁed carcinoma mucin led to
thrombi formation that was dependent both on the presence
of P- and L-selectin. Recently, the molecular mechanism of
mucin-induced initiation of tumor cell-platelet complexes
has been described [32]. Microthrombi formation induced
by carcinoma mucins was found to be dependent on L-
selectin and PSGL-1 expression on neutrophils that induced
cathepsin G release thereby triggering platelet activation and
P-selectin expression.
3.3. L-Selectin and Metastasis. Participation of leukocytes in
platelet-tumor cell emboli is well described, yet the role of
leukocytes in the process of metastatic initiation remains
under investigation. The establishment of a metastatic niche
is based on the initial recruitment of bone marrow-derived
cells to distant sites in organs where metastatic cells tend
to seed [33, 34]. In general, contribution of leukocytes to
metastasis largely depends on spatial and temporal situation
that is deﬁned by the microenvironment and tumor cells
[34–36]. Whether L-selectin mediates leukocyte recruitment
to metastatic sites has been tested in L-selectin-deﬁcient
mice [21, 37]. The absence of L-selectin led to signiﬁcant
attenuation of metastasis, indicating that L-selectin actively
contributes to leukocyte recruitment and formation of a
metastatic niche [5, 38]. Reduced numbers of CD11b-
positive leukocytes has been detected at early time points
after tumor cell injection that correlated with reduced tumor
cell survival in the lungs [37]. Recent evidence indicates that
selectin-mediated interactions through cooption of inﬂam-
matory pathways contribute to formation of a permissive
microenvironment for metastasis [38]. Tumor cell-mediated
activation of the adjacent endothelium upon vascular arrest
resulted in NF-κB activation and expression of E-selectin,
thereby contributing to metastasis.
3.4. E-Selectin and Metastasis. E-selectin has been inves-
tigated as a mediator of metastasis at sites where arrest
of tumor cells in the microvasculature has been observed
[39, 40]. E-selectin expressed on activated endothelial cells
has been detected during metastatic colonization of the liver
[39, 41]. Inhibition of E-selectin or downregulation of E-
selectin expression resulted in attenuation of experimental
liver metastasis. In contrast, transgenic overexpression of
E-selectin in the liver redirected metastasis to this organ,
thereby conﬁrming the role of E-selectin in this process.
Interestingly, experimental metastasis of human colon carci-
noma cells lines was not aﬀected by the absence of E-selectin
[24].However,spontaneousbreastmetastasistothelungwas4 International Journal of Cell Biology
reduced in E-selectin-deﬁcient mice, indicating E-selectin
involvement during lung metastasis [42]. Organ-speciﬁc
diﬀerences may contribute to the colonization process and
diﬀerent requirements for selectin-mediated interactions
may be dependent on the primary tumor and the metastatic
organ.
While selectins were identiﬁed as potential facilitators of
metastasis, they have not been explored as pharmacological
targets for treating cancer progression.
4.Biology ofIntegrins
Integrins are large and complex transmembrane glycopro-
teins. The structure of integrins consists of two distinct
chains, α-a n dβ-subunit, which form a non-covalent het-
erodimer [43, 44]. In mammals, 18 α-a n d8β-integrins have
been characterized that combine to form 24 unique canon-
ical α/β receptors identiﬁed so far. Integrins mediate cell
adhesion and directly bind components of the extracellular
matrix (ECM), such as ﬁbronectin, vitronectin, laminin, or
collagen, thereby providing anchorage for cell motility and
invasion.Sincespeciﬁcintegrinscanbindtodiﬀerentligands
and identical ligand can be shared by diﬀerent integrins, this
redundancy underscores the general importance of integrins
in cell communication.
Integrins are mediators of a bidirectional signaling where
intracellular signals induce alterations in the conformation,
thusligand-bindingproperties(inside—outsignaling).Since
integrins are linked to cytoskeletal structures (e.g., α-actinin,
talin,andvinculin)ligationofextracellularligandscaninﬂu-
ence intracellular processes (outside—in signaling) through
activation of kinases, GTPases of the Ras/Rho signaling
pathways[44,45].Theconvergencebetweenthecytoskeleton
and ECM components is mediated via a cluster formation
of integrins and their downstream signaling molecules, focal
adhesion kinase (FAK) or Src family kinases, which aﬀect
the cellular shape and migratory properties of cells [46].
In addition to the well-established role of integrins during
migration and invasion, integrins also regulate cell pro-
liferation, survival and angiogenesis, all processes actively
investigated during cancer progression.
5.IntegrinsduringCancerMetastasis
The ubiquitous presence of integrins on tumor cells, blood
components, vasculature, and stromal cells suggest that inte-
grins might essentially contribute to diﬀerent steps in the
metastatic cascade. As many human tumors originate from
epithelial cells, integrins expressed on epithelial cells are
generally present also in tumor cells. Studies correlating
integrin expression levels with the pathological outcomes,
such as metastasis or patient survival, have identiﬁed several
integrins that might be involved in cancer progression [6].
Tumor cell expression of αvβ3, αvβ5, α5β1, α6β4 correlated
with metastatic progression in melanoma, breast carcinoma,
prostate and pancreatic and lung cancer [6].
During hematogenous phase of metastasis tumor cell
platelet interaction are mediated either by P-selectin (see
above) or through platelet integrin αIIbβ3. Inhibition of
αIIbβ3 integrin or P-selectin by function-blocking anti-
bodies signiﬁcantly reduced platelet-tumor cell interaction
and tumor cell adhesion on activated endothelium [47–49].
Accordingly, attenuation of metastasis has been observed.
Tumor cell expression of αvβ3 integrin together with
its capacity to bind several ECM components, including
ﬁbronectin, vitronectin, and osteopontin, has been regarded
as critical factor for aﬀecting the site of metastasis. In
this respect, ﬁbrinogen was identiﬁed as a bridging factor
betweenαIIbβ3integrinsonplateletandαvβ3ontumorc ells
[50, 51]. This interaction facilitates tumor cell arrest in the
vasculature and metastasis to various tissues, including bone
marrow and lungs.
The contribution of integrins to angiogenesis and there-
by tumor progression and metastasis has recently been
reviewed [52]. Tumor-associated vessels express αvβ3a n d
αvβ5 integrins that were not detected in quiescent vascula-
ture [53]. The binding of these vascular integrins to ECM
components in the tumor microenvironment contributes
to invasion and migration of endothelial cells. Therefore,
targeting of αvβ3a n dαvβ5 integrins with antibodies or
peptide- (RGD-) derived structures has been investigated as
a promising antiangiogenic approach.
The establishment of metastatic niche is dependent on
therecruitmentofbonemarrow-derivedcells[33,34].Hom-
ing of circulating progenitor cells to tumors was shown to
require α4β1 integrins [54]. Expression of integrin α4β1
(VLA-4) on bone marrow-derived cells mediates binding to
VCAM and cellular ﬁbronectin, which are present at sites of
endothelial remodeling.
Initial studies on the role of integrins during metasta-
sis, speciﬁcally investigating primary endothelial contacts,
were focused on melanoma metastasis [55–57]. Metastatic
dissemination of murine melanoma B16F10 cells has been
blocked by peptide displaying the RGD integrin-binding
sequence of ﬁbronectin [55]. The targeted integrin involved
in the vascular arrest of melanoma cells has later been identi-
ﬁed to be VLA-4 [56, 57]. Experimental pulmonary metasta-
sis of melanoma cell lines, B16 and A 375M, was conﬁrmed
to be mediated by VLA-4. The speciﬁc VLA-4-mediated
interaction with VCAM-1 on endothelium is required for
melanoma cell adhesion and endothelial transmigration
[58]. Recently, VLA-4 mediated melanoma adhesion to
VCAM-1 on activated endothelium was shown to support
extravasation under the shear ﬂow also in the absence of
selectin ligands [59], indicating the potential of VLA-4 to
serve as an adhesion molecule during metastatic spread of
cancer.
Besides the role of VLA-4 in melanoma metastasis, β1
integrins strongly contribute to metastasis of other tumor
types, for example, lymphomas [60]. Silencing of β1 inte-
grins in the highly metastatic Esb murine T-lymphoma cell
line, and thus the loss of VLA-4 and VLA-6 binding, strongly
reducedthemetastaticdisseminationtothelungsandspleen.
Furthermore, a change in metastatic pattern with prevalence
for skeletal muscle invasion has been observed [60]. To
investigate the role of β1 integrins during tumor growth and
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gene has been generated [61]. Overexpression of β1 integrin
signiﬁcantly correlated with metastatic spread of these cells
to the lung and liver, when compared with parental cells with
disrupted β1 integrin gene [61]. Taken together, integrins
are becoming attractive therapeutic targets for therapeutic
strategies focused not only on tumor development but also
on metastasis.
Since heparins eﬀectively block both P-, L-selectins and
VLA-4 integrin-mediated tumor cell adhesion, heparin and
heparin derivatives have been tested in a number of animal
models for their potential to attenuate metastasis (reviewed
in [9]).
6. Heparinand Cancer:ClinicalEvidence
Heparin is commonly used for the prevention or treatment
of venous thromboembolism in cancer patients. In addition
to its antithrombotic activity, cancer patients treated with
heparins showed an improved survival in a number of
retrospective and prospective studies (reviewed in [62, 63]).
A recent review on antithrombotic therapy using heparins
concluded that, despite the heterogeneity of completed
clinical studies, heparin treatment of cancer patients with
better prognosis is beneﬁcial for patients primarily due to
prolonged survival [10]. Based on this conclusion, together
with observations from animal models, heparin appears to
directly aﬀect cancer progression associated with metastatic
spread.
7. HeparinAttenuatesMetastasisthrough
Inhibitionof Selectins
Heparin is a complex mixture of natural glycosaminogly-
cans based on repeating disaccharide units containing glu-
cosamine and glucuronic/iduronic acid residue with a high
degree of sulfation [64]. Heparin and LMWH were tested in
many diﬀerent animal models for their potential to inhibit
cancer progression primarily using experimental metastasis
models (reviewed in [65, 66]). Despite large variation in
heparin preparations, doses applied, time of application, and
diﬀerent tumor models, attenuation of metastasis has been
observedalmostinallindependentstudieswhenheparinwas
applied around the time of tumor cell injection. Together
with the limited eﬀect on tumor growth [67, 68], these ﬁnd-
ings indicate that heparin aﬀects processes when tumor cells
arestillinthebloodcirculation.Becauseoftheverynatureof
heparin, several other biological activities in addition to the
anticoagulant activity have been detected such as binding to
cell adhesion molecules (P- and L-selectin, VLA-4 integrin),
enzymes (heparanase), growth factors, and cytokines [69–
73]. Chemically modiﬁed heparins were prepared and tested
for various biological activities [71]. Modiﬁed heparins
containing mostly P-selectin inhibitory activity were shown
to eﬃciently attenuate metastasis almost to the same levels
as observed in P-selectin-deﬁcient mice [71]. Since heparin
injection in P-selectin-deﬁcient mice resulted in no further
attenuation of metastasis, these ﬁndings indicated that
heparin aﬀects metastasis by inhibition of P-selectin [7, 29,
71]. Interestingly, a single dose of heparin prior to tumor cell
injectionfurtherattenuatedmetastasisinL-selectin-deﬁcient
mice, indicating that L-selectin involvement in this process is
subsequenttoP-selectin[21].Furtherevidenceforsequential
involvement ofP-andL-selectininmetastasiswasconﬁrmed
by observation that L-selectin contributes to metastasis
ﬁrst several hours after tumor cell injection [37]. Heparin
injection 6–12 hours after the tumor cell challenge further
reduced metastasis in P-selectin-deﬁcient mice conﬁrming
the potential of heparin to inhibit also L-selectin-mediated
interactions. Taken together, these ﬁndings indicate that
inhibition of P- and L-selectin attenuates metastasis and
heparinsappeartobeeﬃcientinhibitorsofselectinmediated
interactions in vivo.
8. HeparinBindingandInhibitionof
Integrin Functions
Heparin as a potential inhibitor of integrin-mediated cell-
cell interaction has been evaluated only in few studies. The
αMβ2 (Mac-1) integrin on hematopoietic progenitor cells
was shown to mediate adhesion to stromal compartment
through binding to heparin and heparan sulfate [74, 75].
Another study described the leukocyte integrin αXβ2 to bind
sulfated heparin in a low micromolar range [76]. These
studies suggest that heparin can interfere with leukocyte
binding and recruitment to the endothelium.
Zhang et al. reported that platelet integrin αIIbβ3c a n
eﬃciently be blocked by heparin and non-anticoagulant
heparin derivatives [77]. Platelet interaction with melanoma
cells A375 or B16F10 was strongly reduced in vitro and
metastasis in vivo. These ﬁndings indicate that heparin inhi-
bition of αIIbβ3 integrins is additional to P-selectin inhibi-
tion of platelet binding (as mentioned above) with relevance
for those tumors cells with low expression levels of P-selectin
ligands.
Heparin inhibition of integrin-mediated melanoma ad-
hesion to endothelium has been reported only recently [73].
Expression of integrin α4β1 (VLA-4) by B16F10 melanoma
cells mediated their adhesion to endothelial cells through
binding to VCAM-1. Heparin was shown to inhibit the
VLA-4 mediated melanoma binding to VCAM-1 substrates
under dynamic conditions. A follow-up study using human
melanoma MV3 cells conﬁrmed heparin binding to VLA-
4 with binding aﬃnities in the low micromolar range [78].
Structural analysis of heparin indicated a size dependency
of integrin binding, since short heparin fragment or the
pentasaccharide (Fondaparinux) was not able to bind VLA-4
[8]. Further analysis revealed that also the sulfation density is
critical for VLA-4 recognition [79].
Altogether, these studies indicate that heparin can aﬀect
important steps in the metastatic cascade by inhibition of
integrins. The relevance of this contribution depends on
tumor cell types carrying integrin and/or selectin ligands.
Melanoma cells with their high expression levels of VLA-4
appear especially relevant for this consideration. However,
the eﬃciency to inhibit metastasis in vivo remains to be
analyzed.6 International Journal of Cell Biology
9.Tumor CellSeedingandtheEstablishment of
MetastaticNiche
Beside direct heparin inhibition of adhesion receptor func-
tions, heparin can aﬀect the activities of cellular proteogly-
cans related to cell adhesion. This possibility will shortly be
introduced below with respect to potential antimetastatic
approaches or novel targets.
Chemokinesarechemotacticcytokinesthatinducedirect
migration of leukocytes to sites of inﬂammation or cancer
progression [80]. Beside the well-described role of chemok-
ines during inﬂammation, seeding of tumor cells to distant
tissues was shown to be facilitated by chemokines.
There is compelling evidences that chemokine receptors,
for example, CXCR4, mediate breast cancer metastasis [81].
Breast cancer cells expressing CXCR4 in circulation eﬀec-
tively enter the bone marrow niche due to enhanced expres-
sion of CXCL12 in this environment [82]. Targeted metasta-
sis to the bone marrow or other sites with high expression
of CXCL12 has been described in a number of cancers
including breast, colon, and prostate [80]. Chemokines bind
to glycosaminoglycans chains of proteoglycans presented on
surfaces of epithelial and vascular endothelial cells or on
extracellular matrix molecules. Cell migration is dependent
on chemokine gradient presented by chemokines at speciﬁc
sites [83]. Recently, syndecan-1 and syndecan-4 proteogly-
cans were shown to be required for chemokine- (CCL5-)
induced hematoma migration and invasion [84]. Similarly,
CCL2-inducedhumanhepatomacellmigrationandinvasion
has been blocked by anti-syndecan-1 and -4 antibodies, but
also when hepatoma cells were pretreated with heparitinases
that remove glycosaminoglycans from cell surfaces [85].
Interestingly, a recent study reported on the ability of LMW
heparin to bind SDF-1 (CXCL-12) in a sub-micromolar
range [86]. Since proper chemokine presentation by endoge-
nous proteoglycans is a prerequisite for successful metastasis,
heparin treatment might “remove” chemokine as a decoy
and thereby reduce tumor cell adhesion and recruitment to
the metastatic sites. Chemokine binding to its chemokine
receptor could directly activate integrin binding function by
inducing the conformational change of the integrins [44].
Whether heparin binding to chemokines indeed attenuates
metastasis remains to be explored.
Fibronectin, an ECM protein, possesses speciﬁc and
partlyoverlappingbindingsitesfortheintegrinVLA-4,VLA-
5, and heparin [87]. The anchorage of cells to heparin-
binding domains of ﬁbronectin or other ECM components
is mainly linked to syndecans. Several studies point to the
critical role of the syndecan extracellular domains in tumor
celladhesionandinvasionbehaviorwheresyndecan-4actsas
a “coreceptor” with integrin VLA-5, but not VLA-4 [43, 88].
Syndecan-4 binds to the extracellular matrix and is also
connected to the actin cytoskeleton via interaction with
structural and signaling proteins such as FAK, syndesmos,
andpaxillin.Thisrepresentsbothamechanicalandsignaling
linktocellsurfaceintegrinVLA-5requiredforfocaladhesion
a n ds t r e s sﬁ b e rf o r m a t i o ni nc e l l sa d h e r e n tt oﬁ b r o n e c t i n
[89, 90]. Thus, the potential heparin antimetastatic activ-
ity can be based on interference either directly with the
integrin-ﬁbronectin binding or indirectly via competing
for the proteoglycan binding of syndecan-4 to ﬁbronectin.
However, a direct interference of heparin with this pathway
in cell migration remains to be deﬁned.
Integrins were also shown to bind cystein-rich protein
61—Cyr61[91].Cyr61wasﬁrstidentiﬁedasagrowthfactor-
inducibleimmediateearlygeneandbelongstotheCCNfam-
ily of matricellular proteins (CCN1). Elevated levels of Cyr61
have been correlated with increased breast adenocarcinoma,
endometrial tumors, pancreatic cancer, or glioma malig-
nancy [92–95]. Cyr61 has been reported to mediate numer-
ous cellular processes, such as cell adhesion, cell survival,
proliferation, enhancement of growth factor-induced DNA
synthesis, and angiogenesis [96]. These eﬀects result, at
least in part, through a direct binding of Cyr61 to the
extracellular regions of the integrin αvβ3 thus activating
these adhesion and signaling receptors [97]. However, Cyr61
has also a binding ability to α2β1, α3β1, α5β1, α6β1, and
αMβ2[ 91]. Cyr61 overexpression in gastric cancer cell line
AGSwasshowntoincreaseperitonealdisseminationthrough
increased α2β1 integrin activity [92]. In contrast, Cyr61
silencing in PC-3 and DU-145 prostate cancer cells strongly
inhibited proliferation[98].Though,Cyr61alsosigniﬁcantly
enhanced TRAIL-induced apoptosis through interaction
with integrins αvβ3a n dα6β4[ 98]. Therefore, inhibition of
Cyr61 activity appears as a promising therapeutic approach
to inhibit tumor cell growth, migration, and adhesion. The
Cyr61 molecule has two discrete heparin binding sites which
contribute to binding to cell surface on heparan sulfate pro-
teoglycans on Syndecan-4 [91]. Consequently, heparin could
indirectly inﬂuence integrin functions by depleting released
Cyr61. Although, previous heparin treatment in a number
of animal models might have aﬀected also Cyr61 activity,
further analysis is required to elucidate the relevance of this
signaling pathway for antiadhesive approaches of heparin
applications.
10. Conclusions
Accumulating evidence from several preclinical models con-
ﬁrms that tumor cell interactions through selectins and inte-
grins actively contribute to the metastatic spread of tumor
cells. However, the current cancer therapies are focused only
on targeting of tumor cells while no speciﬁc therapy for
inhibition of metastatic spread is available. Clinical ﬁndings
suggest that heparin and LMW heparin possess anticancer
activities leading to survival beneﬁts for cancer patients in
the early stage of the disease. Although the identiﬁcation of
underlying molecular mechanisms is still ongoing, several
preclinical studies conﬁrmed the dominant contribution of
selectins to metastasis and their role as primary targets of
heparin.
In addition, integrins were shown to contribute to cancer
progression. Since heparin binds to particular integrins im-
plicated in metastasis, targeting integrins opens additional
ways for interference with metastatic progression in addition
to inhibition of angiogenesis, cell migration, or establish-
ment of the premetastatic niche.International Journal of Cell Biology 7
The elucidation of the orchestrated functions of selectin
and integrins and possibly other adhesion molecules during
metastatic cascade requires further studies. Clearly further
clariﬁcation of heparin interactions with selectins and inte-
grins is required, yet the abundant clinical experience with
heparin and LMW heparin proposes its evaluation as a
potential antimetastatic treatment.
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